Pulse Biosciences, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Pulse Biosciences, Inc. (PLSE) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$53.59 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2025-03-31
- Pulse Biosciences, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$53.59M.
- Pulse Biosciences, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$42.21M.
- Pulse Biosciences, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$58.51M.
- Pulse Biosciences, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2021 was -$63.66M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2024-12-31 | -$53.59M 10-K · filed 2025-03-31 |
| 2023-12-31 | -$42.21M 10-K · filed 2025-03-31 |
| 2022-12-31 | -$58.51M 10-K · filed 2024-03-28 |
| 2021-12-31 | -$63.66M 10-K · filed 2023-03-31 |
| 2020-12-31 | -$49.85M 10-K · filed 2023-03-31 |
| 2019-12-31 | -$46.97M 10-K · filed 2022-03-31 |
| 2018-12-31 | -$37.55M 10-K · filed 2021-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iRhythm Holdings, Inc. (IRTC) | United States | $3.651B | -281.06 |
| ICU MEDICAL INC/DE (ICUI) | United States | $4.153B | 18.85 |
| Heartflow, Inc. (HTFL) | United States | $4.225B | |
| AtriCure, Inc. (ATRC) | United States | $3.089B | |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| NovoCure Ltd (NVCR) | $1.886B | -11.87 |